Theravance Biopharma
TBPH
TBPH
120 hedge funds and large institutions have $600M invested in Theravance Biopharma in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $655M → $600M (-$55M)
74% less call options, than puts
Call options by funds: $1.49M | Put options by funds: $5.71M
Holders
120
Holding in Top 10
1
Calls
$1.49M
Puts
$5.71M
Top Buyers
| 1 | +$26.9M | |
| 2 | +$7.18M | |
| 3 | +$6.2M | |
| 4 |
Goldman Sachs
New York
|
+$6.05M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.97M |
Top Sellers
| 1 | -$26M | |
| 2 | -$7.73M | |
| 3 | -$7.25M | |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$5.53M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.75M |